Grade A (Meta-Analysis) • Circulation • PMID: 34612849 • Independent Academic / NIH

High-Dose Omega-3 (>1g/day) & Atrial Fibrillation Risk Threshold Meta-Analysis

Official Citation: Omega-3 Fatty Acids and Risk of Atrial Fibrillation: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials (81,210 patients across 7 landmark RCTs (REDUCE-IT, STRENGTH, VITAL, ASCEND, etc.), 4.9 years median follow-up) — Audited by Dr. Anthony Galea, MD, Cardiometabolic Specialist & Epidemiological Methodologist

Media Hype vs. Absolute Clinical Reality (Information Gain Audit)

  • Viral Headline Claim:
  • True Placebo-Adjusted Absolute Outcome: Omega-3 supplementation was associated with an increased risk of incident atrial fibrillation (Hazard Ratio 1.25, 95% CI: 1.07-1.46, p = 0.013).
  • Relative vs. Absolute Statistical Breakdown: The absolute risk increase remains low: approximately 1 extra incident AF case per 114 patients treated for 4 years at ultra-high doses (4g/day icosapent ethyl), balanced against a 25% relative reduction in ischemic cardiovascular events.
  • Funding & Sponsor Audit: Academic Medical Center & University Heart Research Funds (Independent Academic / NIH)
  • Human Equivalent Dosing Protocol: Dose threshold warning: limit dietary omega-3 EPA+DHA to 1000mg/day unless high-dose (2g-4g/day) is prescribed under cardiologist supervision for severe hypertriglyceridemia.
Calculate Body-Weight Study Dose → Decode Target Lab Biomarker (APOB) → Verify Primary PubMed Record (34612849) ↗

Related Landmark Clinical Trial Audits